Download App

Log in to access Online Inquiry
Company Overview More
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
CEO: Islam J.D., Saqib
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

SWTX SpringWorks Therapeutics
38.000+0.810+2.18%
Post Mkt Price
38.00000.00%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Assets
Current assets
Cash, cash equivalents and short term investments
-27.05% 348.27M -26.55% 373.5M -26.55% 373.5M 54.58% 427.91M
-Cash and cash equivalents
-14.14% 81.93M -29.32% 103.96M -29.32% 103.96M 10.63% 93.85M
-Short-term investments
-30.28% 266.34M -25.42% 269.54M -25.42% 269.54M 74% 334.06M
Prepaid assets
87.18% 7.68M 91.47% 9.41M 91.47% 9.41M 144.89% 5.1M
Total current assets
-26.08% 355.95M -25.42% 382.91M -25.42% 382.91M 55.26% 433.01M
Non current assets
Net PPE
318.63% 11.39M 39.02% 4.2M 39.02% 4.2M 183.25% 3.33M
-Gross PPE
318.63% 11.39M 47.01% 5.22M 47.01% 5.22M -- 3.33M
-Accumulated depreciation
-- -- -92.63% -1.02M -92.63% -1.02M -- --
Investments and advances
-47.92% 35.02M 8.58% 62.11M 8.58% 62.11M 1291.96% 55.92M
Other non current assets
3.37% 3.22M 27.54% 3.27M 27.54% 3.27M 50.42% 3.02M
Total non current assets
-32.08% 49.63M 10.81% 69.58M 10.81% 69.58M 764.99% 62.26M
Total assets
-26.87% 405.58M -21.47% 452.49M -21.47% 452.49M 73.11% 495.28M
Liabilities
Current liabilities
Payables
-25.8% 1.65M 154% 3.43M 154% 3.43M 134.77% 2.5M
-accounts payable
-25.8% 1.65M 154% 3.43M 154% 3.43M 134.77% 2.5M
Current accrued expenses
25.44% 16.73M 46.91% 13.3M 46.91% 13.3M 125.94% 18.37M
Current debt and capital lease obligation
-73.71% 327K -15.49% 1.16M -15.49% 1.16M -- 1.26M
-Current capital lease obligation
-73.71% 327K -15.49% 1.16M -15.49% 1.16M -- 1.26M
Current liabilities
24.07% 23.24M 70.18% 29.97M 70.18% 29.97M 120.35% 28.1M
Non current liabilities
Long term debt and capital lease obligation
437.15% 5.54M -90.51% 129K -90.51% 129K -- 367K
-Long term capital lease obligation
437.15% 5.54M -90.51% 129K -90.51% 129K -- 367K
Other non current liabilities
-- -- -- -- -- -- 36.46% 131K
Total non current liabilities
376.59% 5.54M -91.53% 129K -91.53% 129K -16.02% 498K
Total liabilities
44.67% 28.78M 57.31% 30.1M 57.31% 30.1M 114.29% 28.6M
Shareholders'equity
Share capital
0% 5K 0% 5K 0% 5K 25% 5K
-common stock
0% 5K 0% 5K 0% 5K 25% 5K
-Preferred stock
-- 0 -- 0 -- 0 -- 0
Retained earnings
-138.77% -354.31M -146.63% -292.51M -146.63% -292.51M -82.05% -236.44M
Paid-in capital
7.39% 733.48M 5.86% 715.22M 5.86% 715.22M 74.64% 703.09M
Less: Treasury stock
-- 906K -- -- -- -- -- --
Gains losses not affecting retained earnings
-2850.94% -1.46M -860.98% -312K -860.98% -312K -4% 24K
Total stockholders'equity
-29.53% 376.8M -24.17% 422.4M -24.17% 422.4M 71.1% 466.68M
Total equity
-29.53% 376.8M -24.17% 422.4M -24.17% 422.4M 71.1% 466.68M
Currency Unit
USDUSDUSDUSD
Audit Opinions
--Unqualified Opinion----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%